Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms
Cancer Medicine · 2025
DOI: 10.1002/cam4.71015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Guangshuai Teng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Janus Kinase 2, Atrial Fibrillation, Myeloproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Municipal Education Commission Scientific Research Plan Project of Tianjin, National Natural Science Foundation of China, Haihe Laboratory of Cell Ecosystem Innovation Fund.
Abstract (Originalsprache)
Background
The incidence, outcomes and risk factors for AF in the JAK2 V617F ‐positive MPN patients are still unknown.
Methods
The clinical profiles of patients with JAK2 V617F ‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model.
Results
A total of 439 patients were included (age 57 [12–87] years; 51.3% male). AF was associated with higher risks of stroke ( p = 0.036, HR = 1.987, 95% CI 1.047–3.772) and mortality ( p < 0.001, HR = 3.857, 95% CI 1.836–8.103). Multivariable Cox regression showed that TET2 mutation ( p = 0.042, HR = 4.361, 95% CI 1.053–18.056) and increased IL‐1β ( p = 0.012, HR = 5.476, 95% CI 1.547–28.123) were significant risk factors for AF in patients with JAK2 V617F ‐positive MPN. Nomograms were constructed, allowing patients to be categorized into high‐ and low‐risk groups. The 10‐year AF‐free survival rate was significantly lower in the high‐risk group (62% vs. 91.7%; log‐rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high‐risk group was significantly worse than that in the low‐risk group. The use of either interferon‐α or ruxolitinib, was associated with longer AF‐free survival in the high‐risk group ( p < 0.05).
Conclusion
AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL‐1β were independent risk factors of AF in patients with JAK2 V617F ‐positive MPN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
- Department of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin, China.
- Tianjin Institute of Cardiology, Tianjin, China.
- School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China.
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
ORCID-Profile: Yuan Zhou, Tong Liu, Minghui Duan, Jie Bai
Förderung
- Municipal Education Commission Scientific Research Plan Project of Tianjin
- National Natural Science Foundation of China
- Haihe Laboratory of Cell Ecosystem Innovation Fund
Zitieren
APA
Teng, G., Shang, K., Zhang, Y., Duan, Y., Du, C., Wang, Y., Li, Y., Zhang, H., Peng, L., Wei, X., Tse, G., Zhou, Y., Lip, G. Y. H., Liu, T., Yang, W., Duan, M., & Bai, J. (2025). Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms. Cancer Medicine. https://doi.org/10.1002/cam4.71015
Vancouver
Teng G, Shang K, Zhang Y, Duan Y, Du C, Wang Y, et al. Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms. Cancer Medicine. 2025. doi:10.1002/cam4.71015
BibTeX
@article{Teng2025,
author = {Teng, Guangshuai and Shang, Ke and Zhang, Yuhui and Duan, Yifan and Du, Chenxiao and Wang, Yan and Li, Yanqi and Zhang, Huiqin and Peng, Lan and Wei, Xiaojing and Tse, Gary and Zhou, Yuan and Lip, Gregory Y H and Liu, Tong and Yang, Wei and Duan, Minghui and Bai, Jie},
title = {Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71015}
}
EUVIMED